This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zhang, Y.-j.
Right arrow Articles by Moore, J. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zhang, Y.-j.
Right arrow Articles by Moore, J. P.

 Previous Article  |  Next Article 

Journal of Virology, April 1999, p. 3443-3448, Vol. 73, No. 4
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.

Will Multiple Coreceptors Need To Be Targeted by Inhibitors of Human Immunodeficiency Virus Type 1 Entry?

Yi-jun Zhang and John P. Moore*

Aaron Diamond AIDS Research Center, The Rockefeller University, New York, New York

Received 15 October 1998/Accepted 14 December 1998


    ABSTRACT
Top
Abstract
Text
References

Despite being able to use the Bonzo coreceptor as efficiently as CCR5 in transfected cells, pediatric human immunodeficiency virus type 1 isolate P6 was unable to replicate in peripheral blood mononuclear cells (PBMC) lacking the CCR5 receptor. Furthermore, its replication in wild-type PBMC was completely inhibited by inhibitors of CCR5-mediated entry. Similarly, maternal isolate M6 could use CCR5, CXCR4, Bonzo, and other coreceptors in transfected cells but was completely sensitive to inhibitors of CCR5- and CXCR4-mediated entry when grown in PBMC. The ability of these viruses to use coreceptors in addition to CCR5 and CXCR4 in vitro was, therefore, irrelevant to their drug sensitivity in primary cells. We argue that CCR5 and CXCR4 should remain the primary targets for antiviral drug development, pending strong evidence to the contrary.


    TEXT
Top
Abstract
Text
References

The entry of human immunodeficiency virus type 1 (HIV-1) into target cells is now known to involve sequential interactions of the viral envelope glycoproteins with CD4 and a coreceptor (5, 7, 16, 35). The coreceptors are members of the seven-transmembrane-spanning, G-protein-coupled receptor superfamily. The first of these proteins identified as being an HIV-1 coreceptor was the CXC chemokine receptor CXCR4, which mediates entry of syncytium-inducing (SI) or T-cell-line-tropic HIV-1 isolates (23). Subsequently, the CC chemokine receptor CCR5 was shown to be the major coreceptor for non-syncytium-inducing (NSI) or macrophage-tropic viruses (2, 11, 14, 18, 19). A nomenclature for HIV-1 phenotype based on coreceptor usage has been proposed, in which viruses able to use CXCR4 are designated X4, those able to use CCR5 are designated R5, and dual-tropic viruses that can use both receptors are called R5X4 (6).

There is strong genetic evidence that CCR5 is the most important coreceptor for the macrophage-tropic viruses that are commonly transmitted between individuals (13, 27, 31, 44). There is also good circumstantial evidence that CXCR4 is the most relevant coreceptor for the T-cell-line-tropic isolates that emerge in a substantial fraction of individuals after several years of HIV-1 infection (8, 12, 28, 49). These coreceptors are, therefore, of clear and obvious interest as targets for antiviral drug development. However, at least 10 other members of the G-protein-coupled receptor superfamily have been shown to have HIV-1 coreceptor activity to greater or lesser extents, when transfected into barren target cells and tested in viral entry and/or fusion assays in vitro. These include CCR2b (18), CCR3 (1, 4, 11, 25, 39), BOB/GPR15 (15, 21, 22), Bonzo/STRL33/TYMSTR (3, 15, 21, 30, 32), GPR1 (21, 22), CCR8 (26, 41), US28 (38), V28/CX3CR1 (41), APJ (10, 20), and ChemR23 (43). Of these, CCR3 functions most efficiently, with the broadest range of isolates. The question then arises as to whether any among this eclectic gallimaufry of coreceptors is of importance when considering drug development strategies. Will HIV-1 when faced with, e.g., a CCR5-specific inhibitor simply evade the drug by using a different coreceptor in vivo? To a substantial extent, this question can be answered only by clinical trials of coreceptor-targeted inhibitors in humans or animals. However, to gain some insights into the nature of the problem, we have studied an unusual series of pediatric HIV-1 isolates that are able to use the coreceptors CCR5, Bonzo, and in the case of SI variants, CXCR4, CCR8, V28/CX3CR1, and APJ with approximately equivalent efficiencies in vitro (53). Specifically, we have addressed the issue of whether the ability of these viruses to use Bonzo and other coreceptors affects their sensitivity to inhibitors directed against CCR5 and CXCR4 in primary, CD4+ T cells.

Growth of Bonzo coreceptor-using HIV-1 in wild-type and Delta 32-CCR5 peripheral blood mononuclear cells (PBMC). Viruses designated M6 were isolated from an HIV-1-infected mother who has since died of AIDS (9, 53). They are of the SI phenotype and can use CCR5, CXCR4, Bonzo, CCR8, V28/CX3CR1, and APJ when these coreceptors are expressed in transfected GHOST or U87-CD4 cells in vitro (53). The P6 isolates are from the mother's younger, vertically infected child, are of the NSI phenotype, and use both CCR5 and Bonzo in vitro (53). We have previously shown that Bonzo usage by the M6 and P6 isolates is efficient, to an extent comparable with CCR5 use, which is unusual (21, 53).

We first addressed whether these isolates were able to replicate in PBMC from a human homozygous for defective CCR5 alleles (Delta 32-CCR5), using procedures described previously (51, 53). The maternal (M6) isolate replicated both in the Delta 32-CCR5 cells and in PBMC from a wild-type donor (Fig. 1). The same was also true of other X4 and R5X4 viruses, NL4-3, AD73, and DH123, which is consistent with the ability of all these viruses to use CXCR4, a protein expressed normally on Delta 32-CCR5 cells (31, 51). In contrast, the infant (P6) isolate, like the control SF162 R5 isolate, was completely unable to replicate in the Delta 32-CCR5 cells, although these viruses grew efficiently in wild-type cells (Fig. 1). Similar results were obtained in more-stringent cocultivation assays, in that no replication of P6 and SF162 could be detected in Delta 32-CCR5 cells even when they were subsequently cocultivated for 7 days with phytohemagglutinin-activated PBMC from a donor wild type for CCR5 (data not shown). Thus, the ability of the P6 isolate to use Bonzo in transfected cells is irrelevant to its replication in primary PBMC; the absence of CCR5 from the Delta 32-CCR5 cells is clearly not overcome by Bonzo usage.


View larger version (108K):
[in this window]
[in a new window]
  		FIG. 1.   Replication of HIV-1 isolates in PBMC from wild-type and Delta 32-CCR5 donors. The HIV-1 isolates indicated were tested for their ability to replicate in mitogen-stimulated PBMC from wild-type (a) and Delta 32-CCR5 (b) donors. Virus replication was assessed by p24 antigen production on days 4, 7, and 11, as described previously (51, 53). The coreceptors that can be used by each isolate is given in panel a. For M6-V3 and DH123, this is incomplete, and a more-detailed description is provided elsewhere (53). Similar results were obtained with cells from two donors and when other isolates of the P6 and M6 series were tested.

Sensitivity of Bonzo coreceptor-using HIV-1 to CCR5- and CXCR4-directed inhibitors. We next assessed the sensitivity of the Bonzo-using P6 and M6 isolates to RANTES and aminoxypentane-RANTES (AOP-RANTES), two inhibitors of HIV-1 entry via CCR5 (14, 19, 33, 48, 51) (Fig. 2). Like other isolates able to use CXCR4, replication of the M6 isolate in CCR5 wild-type donor PBMC was only weakly inhibited by RANTES and AOP-RANTES, since entry via CXCR4 is unhindered (Fig. 2). In contrast, the replication of P6 isolates (R5/Bonzo) was as sensitive as the replication of the P4 and SF162 isolates (R5) to RANTES and AOP-RANTES (Fig. 2). The inhibition was dose dependent and eventually complete for all these isolates, showing that Bonzo usage did not permit HIV-1 to evade CCR5-directed inhibitors in PBMC. Of note is the fact that, although the natural ligands for Bonzo are unknown, there is no evidence that Bonzo is a RANTES receptor; RANTES does not block P6 replication in GHOST-Bonzo cells (data not shown).


View larger version (94K):
[in this window]
[in a new window]
  		FIG. 2.   Sensitivity of HIV-1 isolates to RANTES and AOP-RANTES in wild-type PBMC. The HIV-1 isolates indicated were tested for their ability to replicate in mitogen-stimulated PBMC from a wild-type donor in the presence of the indicated concentrations of RANTES (a) or AOP-RANTES (b). Virus replication was assessed by p24 antigen production on day 7 and related to the amount produced in the absence of inhibitor (defined as 100%). The isolates to the left of the broken line in each panel can use CXCR4; those to the right cannot. Similar results were obtained with cells from two donors and with other isolates of the P6 and M6 series.

To test the sensitivity of HIV-1 replication to a CXCR4-specific inhibitor, we used the bicyclam AMD3100 (17, 45, 46) (Fig. 3). In PBMC from CCR5 wild-type donors, AMD3100 significantly but only partially inhibited the replication of the dual-tropic M6 isolate, which can still enter the cells via CCR5. The X4 virus NL4-3 was completely inhibited by AMD3100, but the R5/Bonzo virus P6 was insensitive, as expected (Fig. 3a). When PBMC from a Delta 32-CCR5 donor were used, M6 and the control DH123 and NL4-3 isolates were all completely (or almost completely) inhibited by AMD3100 (Fig. 3b). In other experiments, the M6 isolate, which can use Bonzo as well as CXCR4, was indistinguishable from DH123, which cannot use Bonzo, in its sensitivity to AMD3100 (data not shown). Thus, the ability to use Bonzo does not allow HIV-1 to evade a CXCR4-specific inhibitor. Furthermore, although both DH123 and M6 can also use several other coreceptors in transfected cells, including CCR8, V28/CX3CR1, and APJ (53), they are still sensitive to a CXCR4-specific inhibitor in Delta 32-CCR5 PBMC (Fig. 3b).


View larger version (37K):
[in this window]
[in a new window]
  		FIG. 3.   Sensitivity of HIV-1 isolates to AMD3100 in PBMC from wild-type and Delta 32-CCR5 donors. The HIV-1 isolates indicated were tested for their ability to replicate in mitogen-stimulated PBMC from wild-type (a) and Delta 32-CCR5 (b) donors in the presence of the indicated concentrations of AMD3100. Virus replication was assessed by p24 antigen production on day 4 and related to the amount produced in the absence of inhibitor (defined as 100%). Inhibition of M6 replication by AMD3100 exceeded 99% when the cultures were retested on day 7.

The combination of AOP-RANTES with AMD3100 was used to assess the effects of inhibitors directed at both CCR5 and CXCR4 simultaneously on the infection of healthy donor PBMC by the maternal isolate M6 (Fig. 4). Alone, AOP-RANTES and AMD3100 could only partially inhibit M6 infectivity, but when they were used together, inhibition was complete (Fig. 4). Similar results were obtained with the DH123 isolate (data not shown). Thus, despite the ability of M6 to enter transfected cells via other coreceptors, such as Bonzo, CCR8, V28/CX3CR1, and APJ (53), a combination of a CCR5 inhibitor and a CXCR4 inhibitor was sufficient to block its replication in PBMC from a wild-type CCR5 donor.


View larger version (107K):
[in this window]
[in a new window]
  		FIG. 4.   Complete inhibition of HIV-1 by a combination of AOP-RANTES and AMD3100. Replication of the HIV-1 isolate M6-V3 in PBMC from a wild-type donor was tested in the presence of AOP-RANTES (AOP-R) and AMD3100. These compounds were each tested at 1, 0.1, and 0.01 µg/ml, as indicated by the hatched solid, and white bars, respectively. The same final concentrations of each compound were present in the AOP-RANTES plus AMD3100 combination. Virus replication was assessed by p24 antigen production on days 4 and 7 and related to the amount produced in the absence of inhibitor (defined as 100%).

Discussion. Although SI, T-cell-line-tropic viruses are often able to use multiple coreceptors for entry into transfected cell lines, the efficient use of coreceptors other than CCR5 by NSI, macrophage-tropic HIV-1 strains is rare (21, 53). CCR3 usage by NSI viruses can be demonstrated in transfected cells (1, 4, 11, 25, 39). However, among the many viruses we have tested, only a single set of NSI isolates (P6 series) from an HIV-1-infected child was able to use a receptor other than CCR5 as efficiently as CCR5 itself could be used; these isolates entered Bonzo- or CCR5-expressing cells with approximately equivalent efficiency (53). SI isolates (M6 series) from the mother of this child used CCR5, CXCR4, Bonzo, and other coreceptors (CCR8, V28/CX3CR1, and APJ). The availability of these Bonzo-using isolates allowed us to address whether coreceptors other than CCR5 and CXCR4 are likely to be of significant importance for antiviral drug development strategies aimed at the HIV-1 coreceptors. For example, had we found that an otherwise effective, CCR5-specific inhibitor such as AOP-RANTES was unable to completely inhibit the replication of the P6 isolates in vitro, it would have implied that Bonzo provided an alternative, unhindered route for HIV-1 entry into PBMC. An inference would then be that the acquisition of Bonzo use might be an evolutionary pathway for viral escape from a CCR5-specific inhibitor. Similar arguments could be made for an SI virus such as M6, under the selection pressure of a combination of CCR5- and CXCR4-specific inhibitors.

We observed, however, that the ability of the P6 and M6 viruses to use Bonzo did not overtly affect their sensitivity to AOP-RANTES and AMD3100, alone or in combination, when these were used as prototypic inhibitors of entry via CCR5 and CXCR4, respectively. We cannot exclude the possibility of subtle influences of the usage of Bonzo (or other coreceptors) on drug sensitivity, but the P6 and M6 viruses were neither unusually sensitive or insensitive to AOP-RANTES or AMD3100 in our experience. These experiments therefore suggest that the ability of the P6 and M6 isolates to use Bonzo in transfected cells is irrelevant to their replication in PBMC. This conclusion is further supported by the observation that P6 viruses were unable to replicate in PBMC from a Delta 32-CCR5 homozygous individual. Bonzo (STRL33) is expressed at the mRNA level in PBMC (15, 21, 30) but is not used for entry of the P6 isolate. Furthermore, the replication of the M6 isolate in the Delta 32-CCR5 PBMC was completely blocked by the CXCR4-specific inhibitor AMD3100, despite M6 also being able to use Bonzo, CCR8, V28/CX3CR1, and APJ in transfected cells (53). The same reservations about the relevance of Bonzo usage for HIV-1 replication in PBMC may therefore apply also to CCR8, V28/CX3CR1, and APJ.

Viruses isolated from an HIV-1-infected individual who was homozygous for Delta 32-CCR5 alleles were found to use only CXCR4 when tested against a variety of coreceptor-expressing cell lines in vitro (34). Of note is that the relative levels of mRNAs for several coreceptors in PBMC have been reported to be as follows: CXCR4, 150; CCR5, 100; CCR2b, 15; and CCR3, 10 (36). In addition, fluorescence-activated cell sorting analysis shows that CCR3 is expressed in PBMC at only about 1% of the level of CCR5 expression (42). All of these observations are consistent with a paramount role of CCR5 and CXCR4 for HIV-1 replication in peripheral blood cells. In principle, any of the coreceptors that have been described as functional for HIV-1 entry in transfected cells could provide an escape route for HIV-1 under drug selection pressure in vivo. However, we could find no reason to believe this is likely to occur. We note that an SDF-1 escape mutant of NL4/3, derived in vitro, still retained CXCR4 usage, in a manner that was less sensitive to the inhibitor (29, 45). Coreceptors other than CCR5 and CXCR4 might be important for HIV-1 replication in nonlymphoid cells, including those found at mucosal surfaces (20, 24, 25, 36, 40, 47, 50), in minor lymphocyte subsets (42, 54), or in specialist lymphoid tissues, such as the thymus (especially in infants) (52). However, it has been shown that 99% of virus production in HIV-1-infected people is produced by CD4+ T lymphocytes (37). Inhibition of HIV-1 replication in these cells is of major clinical benefit, so usage of coreceptors other than CCR5 and CXCR4 should not be the primary concern in the development of antiviral compounds directed at blocking HIV-1 entry into CD4+ T cells.

The priority in the development of coreceptor-targeted antiviral compounds should, we believe, remain squarely on CCR5 and CXCR4 pending strong evidence to the contrary. A major issue will be whether the use of a CCR5-specific inhibitor will drive the evolution of an NSI virus towards CXCR4 usage and the consequent acquisition of the SI phenotype. This will require careful evaluation in vitro and in vivo should suitable drugs be developed. However, it is likely that any coreceptor-targeted inhibitors will be used in combination with existing antiviral drugs such as protease and reverse transcriptase inhibitors. Their suppression of HIV-1 replication will reduce the probability of phenotypic evolution. Nonetheless, the powerful potential of HIV-1 to evade any inhibitors of its replication must always be recognized, so the routes it might take in such evasion need to be carefully defined.


    ACKNOWLEDGMENTS

We appreciate the contributions of the donors of HIV-1 isolates and clones used in this study, in particular the participants in the Pediatric AIDS Foundation's ARIEL Project for isolates M6 and P6. We particularly thank Amanda Proudfoot (Serono Research Institute, Geneva, Switzerland) for the gifts of RANTES and AOP-RANTES, Bahige Baroudy (Schering Plough Research Institute, Nutley, N.J.) for AMD3100, and Dan Littman and Vineet KewalRamani for cell lines. We are grateful to Cecilia Cheng-Mayer and Alexandra Trkola for interesting discussions and to Tom Ketas and Ivor Biggun for PBMC preparations.

This study was supported in part by NIH grant AI41420 and by the Pediatric AIDS Foundation, for which J.P.M. is an Elizabeth Glaser Scientist.


    FOOTNOTES

* Corresponding author. Mailing address: Aaron Diamond AIDS Research Center, 455 1st Ave., 7th Floor, New York, NY 10016. Phone: (212) 725-0018. Fax: (212) 725-1126. E-mail: jmoore{at}adarc.org.


    REFERENCES
Top
Abstract
Text
References

1. Alkhatib, G., E. A. Berger, P. M. Murphy, and J. E. Pease. 1997. Determinants of HIV-1 co-receptor function on CC chemokine receptor 3. Importance of both extracellular and transmembrane/cytoplasmic regions. J. Biol. Chem. 272:20420-20426[Abstract/Free Full Text].
2. Alkhatib, G., C. Combadiere, C. C. Broder, Y. Feng, P. E. Kennedy, P. M. Murphy, and E. A. Berger. 1996. CC CKR5: A RANTES, MIP-1alpha , MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 272:1955-1958[Abstract].
3. Alkhatib, G., F. Liao, E. A. Berger, J. M. Farber, and K. C. W. Peden. 1997. A new SIV coreceptor, STRL33. Nature 388:238[Medline].
4. Bazan, H. A., G. Alkhatib, C. C. Broder, and E. A. Berger. 1998. Patterns of CCR5, CXCR4, and CCR3 usage by envelope glycoproteins from human immunodeficiency virus type 1 primary isolates. J. Virol. 72:4485-4491[Abstract/Free Full Text].
5. Berger, E. A. 1997. HIV entry and tropism: the chemokine receptor connection. AIDS 11(Suppl. A):S3-S16.
6. Berger, E. A., R. W. Doms, E.-M. Fenyö, B. T. M. Korber, D. R. Littman, J. P. Moore, Q. J. Sattentau, H. Schuitemaker, J. Sodroski, and R. A. Weiss. 1998. A new classification for HIV-1. Nature 391:240[Medline].
7. Bieniasz, P. D., and B. R. Cullen. 1998. Chemokine receptors and human immunodeficiency virus infection. Front. Biosci. 3:44-58.
8. Björndal, Å., H. Deng, M. Jansson, J. R. Fiore, C. Colognesi, A. Karlsson, J. Albert, G. Scarlatti, D. R. Littman, and E. M. Fenyö. 1997. Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype. J. Virol. 71:7478-7487[Abstract].
9. Cao, Y., P. Krogstad, B. T. Korber, R. A. Koup, M. Muldoon, C. Macken, J. L. Song, Z. Jin, J.-Q. Zhao, S. Clapp, I. S. Y. Chen, D. D. Ho, A. J. Ammann, and the Ariel Project Investigators. 1997. Maternal HIV-1 viral load and vertical transmission of infection: the Ariel Project for the prevention of HIV transmission from mother to infant. Nat. Med. 3:549-552[Medline].
10. Choe, H., M. Farzan, M. Konkel, K. Martin, Y. Sun, L. Marcon, M. Cayabyab, M. Berman, M. E. Dorf, N. Gerard, G. Gerard, and J. Sodroski. 1998. The orphan seven-transmembrane receptor Apj supports the entry of primary T-cell-line-tropic and dualtropic human immunodeficiency virus type 1. J. Virol. 72:6113-6118[Abstract/Free Full Text].
11. Choe, H., M. Farzan, Y. Sun, N. Sullivan, B. Rollins, P. D. Ponath, L. Wu, C. R. Mackay, G. LaRosa, W. Newman, N. Gerard, G. Gerard, and J. Sodroski. 1996. The beta -chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 85:1135-1148[Medline].
12. Connor, R. I., K. E. Sheridan, D. Ceradini, S. Choe, and N. R. Landau. 1997. Change in coreceptor use correlates with disease progression in HIV-1 infected individuals. J. Exp. Med. 185:621-628[Abstract/Free Full Text].
13. Dean, M., M. Carrington, C. Winkler, G. A. Huttley, M. W. Smith, R. Allikmets, J. J. Goedert, S. P. Buchbinder, E. Vittinghoff, E. Gomperts, S. Donfield, D. Vlahov, R. Kaslow, A. Saah, C. Rinaldo, R. Detels, Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study, and S. J. O'Brien. 1996. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion of the CKR5 structural allele. Science 273:1856-1862[Abstract/Free Full Text].
14. Deng, H. K., R. Liu, W. Ellmeier, S. Choe, D. Unutmaz, M. Burkhart, P. Di Marzio, S. Marmon, R. E. Sutton, C. M. Hill, S. C. Peiper, T. J. Schall, D. R. Littman, and N. R. Landau. 1996. Identification of a major coreceptor 5 for primary isolates of HIV-1. Nature 381:661-666[Medline].
15. Deng, H. K., D. Unutmaz, V. N. Kewalramani, and D. R. Littman. 1997. Expression cloning of new receptors used by simian and human immunodeficiency viruses. Nature 388:296-300[Medline].
16. Doms, R. W., and S. C. Peiper. 1997. Unwelcome guests with master keys: how HIV uses chemokine receptors for cellular entry. Virology 235:179-190[Medline].
17. Donzella, G. A., D. Schols, S. W. Lin, J. A. Esté, K. A. Nagashima, P. J. Maddon, G. P. Allaway, T. P. Sakmar, G. Henson, E. De Clercq, and J. P. Moore. 1998. AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nat. Med. 4:72-77[Medline].
18. Doranz, B. J., J. Rucker, Y. Yi, R. J. Smyth, M. Samson, S. Peiper, M. Parmentier, R. G. Collman, and R. W. Doms. 1996. A dual-tropic, primary HIV-1 isolate that uses fusion and the beta -chemokine receptors CKR-5, CKR-2b as fusion cofactors. Cell 85:1149-1159[Medline].
19. Dragic, T., V. Litwin, G. P. Allaway, S. R. Martin, Y. Huang, K. A. Nagashima, C. Cayanan, P. J. Maddon, R. A. Koup, J. P. Moore, and W. A. Paxton. 1996. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 381:667-673[Medline].
20. Edinger, A. L., T. L. Hoffman, M. Sharron, B. Lee, Y. Yi, W. Choe, D. C. Kolson, B. Mitrovic, Y. Zhou, D. Faulds, R. G. Collman, J. Hesselgesser, R. Horuk, and R. W. Doms. 1998. An orphan seven-transmembrane domain receptor expressed widely in the brain functions as a coreceptor for human immunodeficiency virus type 1 and simian immunodeficiency virus. J. Virol. 72:7934-7940[Abstract/Free Full Text].
21. Edinger, A. L., T. L. Hoffman, M. Sharron, B. Lee, B. O'Dowd, and R. W. Doms. 1998. Use of GPR1, GPR15, and STRL33 as co-receptors by diverse human immunodeficiency virus type 1 and simian immunodeficiency virus envelope proteins. Virology 249:367-378[Medline].
22. Farzan, M., H. Choe, K. Martin, L. Marcon, W. Hofmann, G. Karlsson, Y. Sun, P. Barrett, N. Marchand, N. Sullivan, N. Gerard, C. Gerard, and J. Sodroski. 1997. Two orphan seven-transmembrane segment receptors which are expressed in CD4-positive cells support simian immunodeficiency virus infection. J. Exp. Med. 186:405-411[Abstract/Free Full Text].
23. Feng, Y., C. C. Broder, P. E. Kennedy, and E. A. Berger. 1996. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane G protein coupled receptor. Science 272:872-877[Abstract].
24. Ghorpade, A., M. Q. Xia, B. T. Hyman, Y. Persidsky, A. Nukuna, P. Bock, M. Che, J. Limoges, H. E. Gendelman, and C. R. Mackay. 1998. Role of the beta -chemokine receptors CCR3 and CCR5 in human immunodeficiency virus type 1 infection of monocytes and microglia. J. Virol. 72:3351-3361[Abstract/Free Full Text].
25. He, J., Y. Chen, M. Farzan, H. Choe, A. Ohagen, S. Gartner, J. Busciglio, X. Yang, W. Hofmann, W. Newman, C. R. Mackay, J. Sodroski, and D. Gabuzda. 1997. CCR3 and CCR5 are co-receptors for HIV-1 infection of microglia. Nature 385:645-649[Medline].
26. Horuk, R., J. Hesselgesser, Y. Zhou, D. Faulds, M. Halks-Miller, S. Harvey, D. Taub, M. Samson, M. Parmentier, J. Rucker, B. J. Doranz, and R. W. Doms. 1998. The CC chemokine I-309 inhibits CCR8 dependent infection by diverse HIV-1 strains. J. Biol. Chem. 273:386-391[Abstract/Free Full Text].
27. Huang, Y., W. A. Paxton, S. M. Wolinsky, A. U. Neumann, L. Zhang, T. He, S. Kang, D. Ceradini, Z. Jin, K. Yazdanbaksh, K. Kuntsman, D. Erickson, N. R. Landau, J. Phair, D. D. Ho, and R. A. Koup. 1996. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat. Med. 2:1240-1243[Medline].
28. Jansson, M., M. Popovic, A. Karlsson, F. Cocchi, P. Rossi, J. Albert, and H. Wigzell. 1996. Sensitivity to inhibition by beta -chemokines correlates with biological phenotypes of primary HIV-1 isolates. Proc. Natl. Acad. Sci. USA 93:15382-15387[Abstract/Free Full Text].
29. Labrosse, B., A. Brelot, N. Heveker, N. Sol, D. Schols, E. DeClerq, and M. Alizon. 1998. Determinants for sensitivity of human immunodeficiency virus coreceptor CXCR4 to the bicyclam AMD3100. J. Virol. 72:6381-6388[Abstract/Free Full Text].
30. Liao, F., G. Alkhatib, K. W. C. Peden, G. Sharma, E. A. Berger, and J. M. Farber. 1997. STRL33, a novel chemokine receptor-like protein, functions as a fusion cofactor for both macrophage-tropic and T cell line-tropic HIV-1. J. Exp. Med. 185:2015-2023[Abstract/Free Full Text].
31. Liu, R., W. A. Paxton, S. Choe, D. Ceradini, S. R. Martin, R. Horuk, M. E. MacDonald, H. Stuhlmann, R. A. Koup, and N. R. Landau. 1996. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 86:367-378[Medline].
32. Loetscher, M., A. Amara, E. Oberlin, N. Brass, D. F. Legler, P. Loetscher, M. D'Apuzzo, E. Meese, D. Rousset, J.-L. Virelizier, M. Baggiolini, F. Arenzana-Seisdedos, and B. Moser. 1997. TYMSTR, a putative chemokine receptor selectively expressed in activated T cells, exhibits HIV-1 coreceptor function. Curr. Biol. 7:652-660[Medline].
33. Mack, M., B. Luckow, P. J. Nelson, J. Lihak, G. Simmons, P. R. Clapham, N. Signoret, M. Marsh, M. Stangassinger, F. Borlat, T. N. C. Wells, D. Schlöndorff, and A. E. I. Proudfoot. 1998. Aminooxypentane-RANTES induces CCR5 internalization but inhibits recycling: a novel inhibitory mechanism of HIV infectivity. J. Exp. Med. 187:1215-1224[Abstract/Free Full Text].
34. Michael, N. L., J. A. E. Nelson, V. N. KewalRamani, G. Chang, S. J. O'Brien, J. R. Mascola, B. Volsky, M. Louder, G. C. White II, D. R. Littman, R. Swanstrom, and T. R. O'Brien. 1998. Exclusive and persistent use of the entry coreceptor CXCR4 by human immunodeficiency virus type 1 from a subject homozygous for CCR5 Delta 32. J. Virol. 72:6040-6047[Abstract/Free Full Text].
35. Moore, J. P., A. Trkola, and T. Dragic. 1997. Co-receptors for HIV-1 entry. Curr. Opin. Immunol. 9:551-562[Medline].
36. Patterson, B. K., A. Landay, J. Andersson, C. Brown, H. Behbahani, D. Jiyamapa, Z. Burki, D. Stanislawski, M. A. Czerniewski, and P. Barcia. 1998. Repertoire of chemokine receptor expression in the female genital tract. Am. J. Pathol. 153:481-490[Abstract/Free Full Text].
37. Perelson, A., A. U. Neumann, M. Markowitz, J. Leonard, and D. D. Ho. 1996. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 271:1582-1586[Abstract].
38. Pleskoff, O., C. Treboute, A. Brelot, N. Heveker, M. Seman, and M. Alizon. 1997. Identification of a chemokine receptor encoded by human cytomegalovirus as a cofactor for HIV-1 entry. Science 276:1874-1878[Abstract/Free Full Text].
39. Ross, T. M., and B. R. Cullen. 1998. The ability of HIV type 1 to use CCR-3 as a coreceptor is controlled by envelope V1/V2 sequences acting in conjunction with a CCR-5 tropic V3 loop. Proc. Natl. Acad. Sci. USA 95:7682-7686[Abstract/Free Full Text].
40. Rubbert, A., C. Combadiere, M. Ostrowski, J. Arthos, M. Dybul, E. Machado, M. A. Cohn, J. A. Hoxie, P. M. Murphy, A. S. Fauci, and D. Weissman. 1998. Dendritic cells express multiple chemokine receptors used as coreceptors for HIV entry. J. Immunol. 160:3933-3941[Abstract/Free Full Text].
41. Rucker, J., A. L. Edinger, M. Sharron, M. Samson, B. Lee, J. F. Berson, Y. Yi, B. Margulies, R. G. Collman, B. J. Doranz, M. Parmentier, and R. W. Doms. 1997. Utilization of chemokine receptors, orphan receptors, and herpesvirus-encoded receptors by diverse human and simian immunodeficiency viruses. J. Virol. 71:8999-9007[Abstract].
42. Sallusto, F., C. R. Mackay, and A. Lanzavecchia. 1997. Selective expression of the eotaxin receptor CCR3 by human T helper 2 cells. Science 277:2005-2007[Abstract/Free Full Text].
43. Samson, M., A. L. Edinger, P. Stordeur, J. Rucker, V. Verhasselt, M. Sharron, C. Govaerts, C. Mollereau, G. Vassart, R. W. Doms, and M. Parmentier. 1998. ChemR23, a putative chemoattractant receptor, is expressed in monocyte-derived dendritic cells and macrophages and is a coreceptor for SIV and some primary HIV-1 strains. Eur. J. Immunol. 28:1689-1700[Medline].
44. Samson, M., F. Libert, B. J. Doranz, J. Rucker, C. Liesnard, C.-M. Farber, S. Saragosti, C. Lapoumèroulie, J. Cogniaux, C. Forceille, G. Muyldermans, C. Verhofstede, G. Burtonboy, M. Georges, T. Imai, S. Rana, Y. Yi, R. J. Smyth, R. G. Collman, R. W. Doms, G. Vassart, and M. Parmentier. 1996. Resistance to HIV-1 infection of Caucasian individuals bearing mutant alleles of the CCR5 chemokine receptor gene. Nature 382:722-725[Medline].
45. Schols, D., J. A. Este, C. Cabrera, and E. DeClerq. 1998. T-cell-line-tropic human immunodeficiency virus type 1 that is made resistant to stromal cell-derived factor 1alpha contains mutations in the envelope gp120 but does not show a switch in coreceptor use. J. Virol. 72:4032-4037[Abstract/Free Full Text].
46. Schols, D., S. Struyf, J. Van Damme, J. A. Esté, G. Henson, and E. De Clerq. 1997. Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4. J. Exp. Med. 186:1383-1388[Abstract/Free Full Text].
47. Shieh, J. T. C., A. V. Albright, M. Sharron, S. Gartner, J. Strizki, R. W. Doms, and F. Gonzalez-Scarano. 1998. Chemokine receptor utilization by human immunodeficiency virus type 1 isolates that replicate in microglia. J. Virol. 72:4243-4249[Abstract/Free Full Text].
48. Simmons, G., P. R. Clapham, C. Picard, R. E. Offord, M. M. Rosenkilde, T. W. Schwartz, R. Buser, T. N. C. Wells, and A. E. I. Proudfoot. 1997. Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist. Science 276:276-279[Abstract/Free Full Text].
49. Simmons, G., D. Wilkinson, J. D. Reeves, M. T. Dittmar, S. Beddows, J. Weber, G. Carnegie, U. Desselberger, P. W. Gray, R. A. Weiss, and P. R. Clapham. 1996. Primary, syncytium-inducing human immunodeficiency virus type 1 isolates are dual-tropic and most can use either Lestr or CCR5 as coreceptors for virus entry. J. Virol. 70:8355-8360[Abstract].
50. Spira, A. I., P. A. Marx, B. K. Patterson, J. Mahone, R. A. Koup, S. M. Wolinsky, and D. D. Ho. 1996. Cellular targets of infection and route of viral dissemination following intravaginal inoculation of SIV into rhesus macaques. J. Exp. Med. 183:215-225[Abstract/Free Full Text].
51. Trkola, A., W. A. Paxton, S. P. Monard, J. A. Hoxie, M. A. Siani, D. A. Thompson, L. Wu, C. R. Mackay, R. Horuk, and J. P. Moore. 1998. Genetic subtype-independent inhibition of human immunodeficiency virus type 1 replication by CC and CXC chemokines. J. Virol. 72:396-404[Abstract/Free Full Text].
52. Zaitseva, M. B., S. Lee, R. L. Rabin, H. L. Tiffany, J. M. Farber, K. W. C. Peden, P. M. Murphy, and H. Golding. 1998. CXCR4 and CCR5 on human thymocytes: biological function and role in HIV-1 infection. J. Immunol. 161:3103-3113[Abstract/Free Full Text].
53. Zhang, Y.-J., T. Dragic, Y. Cao, L. Kostrikis, D. S. Kwon, D. R. Littman, V. N. KewalRamani, and J. P. Moore. Use of coreceptors other than CCR5 by non-syncytium-inducing adult and pediatric isolates of human immunodeficiency virus type 1 is rare in vitro. J. Virol. 72:9337-9344.
54. Zingoni, A., H. Soto, J. A. Hedrick, F. Stoppacciaro, C. T. Storlazzi, F. Sinigaglia, D. D'Ambrosio, A. O'Garra, D. Robinson, M. Rocchi, A. Santoni, A. Zlotnick, and M. Napolitano. 1998. The chemokine receptor CCR8 is preferentially expressed in Th2 but not Th1 cells. J. Immunol. 161:547-551[Abstract/Free Full Text].

Journal of Virology, April 1999, p. 3443-3448, Vol. 73, No. 4
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Watson, C., Jenkinson, S., Kazmierski, W., Kenakin, T. (2005). The CCR5 Receptor-Based Mechanism of Action of 873140, a Potent Allosteric Noncompetitive HIV Entry Inhibitor. Mol. Pharmacol. 67: 1268-1282 [Abstract] [Full Text]  
  • Princen, K., Hatse, S., Vermeire, K., Aquaro, S., De Clercq, E., Gerlach, L.-O., Rosenkilde, M., Schwartz, T. W., Skerlj, R., Bridger, G., Schols, D. (2004). Inhibition of Human Immunodeficiency Virus Replication by a Dual CCR5/CXCR4 Antagonist. J. Virol. 78: 12996-13006 [Abstract] [Full Text]  
  • Zerhouni, B., Nelson, J. A. E., Saha, K. (2004). CXCR4-Dependent Infection of CD8+, but Not CD4+, Lymphocytes by a Primary Human Immunodeficiency Virus Type 1 Isolate. J. Virol. 78: 12288-12296 [Abstract] [Full Text]  
  • Owen, A., Chandler, B., Bray, P. G., Ward, S. A., Hart, C. A., Back, D. J., Khoo, S. H. (2004). Functional Correlation of P-Glycoprotein Expression and Genotype with Expression of the Human Immunodeficiency Virus Type 1 Coreceptor CXCR4. J. Virol. 78: 12022-12029 [Abstract] [Full Text]  
  • Kuhmann, S. E., Pugach, P., Kunstman, K. J., Taylor, J., Stanfield, R. L., Snyder, A., Strizki, J. M., Riley, J., Baroudy, B. M., Wilson, I. A., Korber, B. T., Wolinsky, S. M., Moore, J. P. (2004). Genetic and Phenotypic Analyses of Human Immunodeficiency Virus Type 1 Escape from a Small-Molecule CCR5 Inhibitor. J. Virol. 78: 2790-2807 [Abstract] [Full Text]  
  • Pollakis, G., Abebe, A., Kliphuis, A., Chalaby, M. I. M., Bakker, M., Mengistu, Y., Brouwer, M., Goudsmit, J., Schuitemaker, H., Paxton, W. A. (2004). Phenotypic and Genotypic Comparisons of CCR5- and CXCR4-Tropic Human Immunodeficiency Virus Type 1 Biological Clones Isolated from Subtype C-Infected Individuals. J. Virol. 78: 2841-2852 [Abstract] [Full Text]  
  • Nabatov, A. A., Pollakis, G., Linnemann, T., Kliphius, A., Chalaby, M. I. M., Paxton, W. A. (2004). Intrapatient Alterations in the Human Immunodeficiency Virus Type 1 gp120 V1V2 and V3 Regions Differentially Modulate Coreceptor Usage, Virus Inhibition by CC/CXC Chemokines, Soluble CD4, and the b12 and 2G12 Monoclonal Antibodies. J. Virol. 78: 524-530 [Abstract] [Full Text]  
  • Veazey, R. S., Klasse, P. J., Ketas, T. J., Reeves, J. D., Piatak, M. Jr., Kunstman, K., Kuhmann, S. E., Marx, P. A., Lifson, J. D., Dufour, J., Mefford, M., Pandrea, I., Wolinsky, S. M., Doms, R. W., DeMartino, J. A., Siciliano, S. J., Lyons, K., Springer, M. S., Moore, J. P. (2003). Use of a Small Molecule CCR5 Inhibitor in Macaques to Treat Simian Immunodeficiency Virus Infection or Prevent Simian-Human Immunodeficiency Virus Infection. JEM 198: 1551-1562 [Abstract] [Full Text]  
  • Willey, S. J., Reeves, J. D., Hudson, R., Miyake, K., Dejucq, N., Schols, D., Clercq, E. D., Bell, J., McKnight, A., Clapham, P. R. (2003). Identification of a Subset of Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus Strains Able To Exploit an Alternative Coreceptor on Untransformed Human Brain and Lymphoid Cells. J. Virol. 77: 6138-6152 [Abstract] [Full Text]  
  • Tsamis, F., Gavrilov, S., Kajumo, F., Seibert, C., Kuhmann, S., Ketas, T., Trkola, A., Palani, A., Clader, J. W., Tagat, J. R., McCombie, S., Baroudy, B., Moore, J. P., Sakmar, T. P., Dragic, T. (2003). Analysis of the Mechanism by Which the Small-Molecule CCR5 Antagonists SCH-351125 and SCH-350581 Inhibit Human Immunodeficiency Virus Type 1 Entry. J. Virol. 77: 5201-5208 [Abstract] [Full Text]  
  • Cilliers, T., Nhlapo, J., Coetzer, M., Orlovic, D., Ketas, T., Olson, W. C., Moore, J. P., Trkola, A., Morris, L. (2003). The CCR5 and CXCR4 Coreceptors Are Both Used by Human Immunodeficiency Virus Type 1 Primary Isolates from Subtype C. J. Virol. 77: 4449-4456 [Abstract] [Full Text]  
  • Seibert, C., Cadene, M., Sanfiz, A., Chait, B. T., Sakmar, T. P. (2002). Tyrosine sulfation of CCR5 N-terminal peptide by tyrosylprotein sulfotransferases 1 and 2 follows a discrete pattern and temporal sequence. Proc. Natl. Acad. Sci. USA 99: 11031-11036 [Abstract] [Full Text]  
  • Clapham, P. R., McKnight, A. (2002). Cell surface receptors, virus entry and tropism of primate lentiviruses. J. Gen. Virol. 83: 1809-1829 [Abstract] [Full Text]  
  • Gorry, P. R., Taylor, J., Holm, G. H., Mehle, A., Morgan, T., Cayabyab, M., Farzan, M., Wang, H., Bell, J. E., Kunstman, K., Moore, J. P., Wolinsky, S. M., Gabuzda, D. (2002). Increased CCR5 Affinity and Reduced CCR5/CD4 Dependence of a Neurovirulent Primary Human Immunodeficiency Virus Type 1 Isolate. J. Virol. 76: 6277-6292 [Abstract] [Full Text]  
  • Thompson, D. A. D., Cormier, E. G., Dragic, T. (2002). CCR5 and CXCR4 Usage by Non-Clade B Human Immunodeficiency Virus Type 1 Primary Isolates. J. Virol. 76: 3059-3064 [Abstract] [Full Text]  
  • Dragic, T. (2001). An overview of the determinants of CCR5 and CXCR4 co-receptor function. J. Gen. Virol. 82: 1807-1814 [Full Text]  
  • Zaitseva, M., King, L. R., Manischewitz, J., Dougan, M., Stevan, L., Golding, H., Golding, B. (2001). Human Peripheral Blood T Cells, Monocytes, and Macrophages Secrete Macrophage Inflammatory Proteins 1{alpha} and 1{beta} following Stimulation with Heat-Inactivated Brucella abortus. Infect. Immun. 69: 3817-3826 [Abstract] [Full Text]  
  • Beaumont, T., van Nuenen, A., Broersen, S., Blattner, W. A., Lukashov, V. V., Schuitemaker, H. (2001). Reversal of Human Immunodeficiency Virus Type 1 IIIB to a Neutralization-Resistant Phenotype in an Accidentally Infected Laboratory Worker with a Progressive Clinical Course. J. Virol. 75: 2246-2252 [Abstract] [Full Text]  
  • Hu, Q.-x., Barry, A. P., Wang, Z.-x., Connolly, S. M., Peiper, S. C., Greenberg, M. L. (2000). Evolution of the Human Immunodeficiency Virus Type 1 Envelope during Infection Reveals Molecular Corollaries of Specificity for Coreceptor Utilization and AIDS Pathogenesis. J. Virol. 74: 11858-11872 [Abstract] [Full Text]  
  • MOORE, J. P., DOMS, R. W. (2000). HIV: Much at Stake with Kidneys?. J. Am. Soc. Nephrol. 11: 2138-2140 [Full Text]  
  • Zhang, Y.-j., Lou, B., Lal, R. B., Gettie, A., Marx, P. A., Moore, J. P. (2000). Use of Inhibitors To Evaluate Coreceptor Usage by Simian and Simian/Human Immunodeficiency Viruses and Human Immunodeficiency Virus Type 2 in Primary Cells. J. Virol. 74: 6893-6910 [Abstract] [Full Text]  
  • Lee, S., Tiffany, H. L., King, L., Murphy, P. M., Golding, H., Zaitseva, M. B. (2000). CCR8 on Human Thymocytes Functions as a Human Immunodeficiency Virus Type 1 Coreceptor. J. Virol. 74: 6946-6952 [Abstract] [Full Text]  
  • Kuhmann, S. E., Platt, E. J., Kozak, S. L., Kabat, D. (2000). Cooperation of Multiple CCR5 Coreceptors Is Required for Infections by Human Immunodeficiency Virus Type 1. J. Virol. 74: 7005-7015 [Abstract] [Full Text]  
  • Sharron, M., Pohlmann, S., Price, K., Lolis, E., Tsang, M., Kirchhoff, F., Doms, R. W., Lee, B. (2000). Expression and coreceptor activity of STRL33/Bonzo on primary peripheral blood lymphocytes. Blood 96: 41-49 [Abstract] [Full Text]  
  • Pöhlmann, S., Lee, B., Meister, S., Krumbiegel, M., Leslie, G., Doms, R. W., Kirchhoff, F. (2000). Simian Immunodeficiency Virus Utilizes Human and Sooty Mangabey but Not Rhesus Macaque STRL33 for Efficient Entry. J. Virol. 74: 5075-5082 [Abstract] [Full Text]  
  • Cormier, E. G., Persuh, M., Thompson, D. A. D., Lin, S. W., Sakmar, T. P., Olson, W. C., Dragic, T. (2000). Specific interaction of CCR5 amino-terminal domain peptides containing sulfotyrosines with HIV-1 envelope glycoprotein gp120. Proc. Natl. Acad. Sci. USA 97: 5762-5767 [Abstract] [Full Text]  
  • De Clercq, E. (2000). Inhibition of HIV Infection by Bicyclams, Highly Potent and Specific CXCR4 Antagonists. Mol. Pharmacol. 57: 833-839 [Abstract] [Full Text]  
  • Steinberger, P., Andris-Widhopf, J., Buhler, B., Torbett, B. E., Barbas, C. F. III (2000). Functional deletion of the CCR5 receptor by intracellular immunization produces cells that are refractory to CCR5-dependent HIV-1 infection and cell fusion. Proc. Natl. Acad. Sci. USA 97: 805-810 [Abstract] [Full Text]  
  • Schramm, B., Penn, M. L., Speck, R. F., Chan, S. Y., De Clercq, E., Schols, D., Connor, R. I., Goldsmith, M. A. (2000). Viral Entry through CXCR4 Is a Pathogenic Factor and Therapeutic Target in Human Immunodeficiency Virus Type 1 Disease. J. Virol. 74: 184-192 [Abstract] [Full Text]  
  • Shieh, J. T. C., Martín, J., Baltuch, G., Malim, M. H., González-Scarano, F. (2000). Determinants of Syncytium Formation in Microglia by Human Immunodeficiency Virus Type 1: Role of the V1/V2 Domains. J. Virol. 74: 693-701 [Abstract] [Full Text]  
  • Trkola, A., Matthews, J., Gordon, C., Ketas, T., Moore, J. P. (1999). A Cell Line-Based Neutralization Assay for Primary Human Immunodeficiency Virus Type 1 Isolates That Use either the CCR5 or the CXCR4 Coreceptor. J. Virol. 73: 8966-8974 [Abstract] [Full Text]  
  • Orsini, M. J., Parent, J.-L., Mundell, S. J., Benovic, J. L. (1999). Trafficking of the HIV Coreceptor CXCR4. ROLE OF ARRESTINS AND IDENTIFICATION OF RESIDUES IN THE C-TERMINAL TAIL THAT MEDIATE RECEPTOR INTERNALIZATION. J. Biol. Chem. 274: 31076-31086 [Abstract] [Full Text]  
  • Esté, J. A., Cabrera, C., Blanco, J., Gutierrez, A., Bridger, G., Henson, G., Clotet, B., Schols, D., De Clercq, E. (1999). Shift of Clinical Human Immunodeficiency Virus Type 1 Isolates from X4 to R5 and Prevention of Emergence of the Syncytium-Inducing Phenotype by Blockade of CXCR4. J. Virol. 73: 5577-5585 [Abstract] [Full Text]  

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zhang, Y.-j.
Right arrow Articles by Moore, J. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zhang, Y.-j.
Right arrow Articles by Moore, J. P.

Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»